Inverness’ even bigger bid for Biosite puts ball back in Beckman’s court
This article was originally published in The Gray Sheet
Executive Summary
Latest salvo in the bidding war for heart test maker Biosite comes from Inverness Medical Innovations, raising its offer to $92.50 per share. Biosite recently inked an amended deal with Beckman Coulter valued at $90 per share to match Inverness' prior unsolicited proposal. Biosite says it is weighing the latest Inverness offer (1"The Gray Sheet" May 7, 2007, In Brief)...